Nxera Pharma Co., Ltd. (TYO: 4565)
Japan
· Delayed Price · Currency is JPY 1,202.00
+8.00 (0.67%)
Nov 12, 2024, 3:40 PM JST
Nxera Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 29,275 | 12,766 | 15,569 | 17,712 | 8,842 | 9,726 | Upgrade
|
| Revenue Growth (YoY) | 136.05% | -18.00% | -12.10% | 100.32% | -9.09% | 173.97% | Upgrade
|
| Cost of Revenue | 5,427 | 3,102 | 926 | 933 | 761 | 851 | Upgrade
|
| Gross Profit | 23,848 | 9,664 | 14,643 | 16,779 | 8,081 | 8,875 | Upgrade
|
| Selling, General & Admin | 14,407 | 8,167 | 3,535 | 3,138 | 2,525 | 2,548 | Upgrade
|
| Research & Development | 11,579 | 10,075 | 7,454 | 5,931 | 3,793 | 4,292 | Upgrade
|
| Other Operating Expenses | -833 | 23 | - | -2 | -1 | 9 | Upgrade
|
| Operating Expenses | 25,153 | 20,063 | 11,831 | 9,869 | 7,227 | 7,915 | Upgrade
|
| Operating Income | -1,305 | -10,399 | 2,812 | 6,910 | 854 | 960 | Upgrade
|
| Interest Expense | -2,209 | -787 | -673 | -518 | -207 | -219 | Upgrade
|
| Interest & Investment Income | 1,481 | 1,225 | 236 | 4 | 35 | 63 | Upgrade
|
| Earnings From Equity Investments | - | - | -429 | 50 | -356 | -181 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -329 | 313 | 22 | -217 | -44 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -282 | 696 | -3,105 | 1,402 | 509 | Upgrade
|
| EBT Excluding Unusual Items | -2,033 | -10,572 | 2,955 | 3,363 | 1,511 | 1,088 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -46 | -1,877 | 208 | -18 | -126 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -62 | - | - | - | 185 | Upgrade
|
| Asset Writedown | - | - | - | -3,138 | 129 | -613 | Upgrade
|
| Pretax Income | -5,108 | -10,680 | 1,078 | 433 | 1,622 | 534 | Upgrade
|
| Income Tax Expense | -1,397 | -3,487 | 696 | -584 | 143 | -898 | Upgrade
|
| Earnings From Continuing Operations | -3,711 | -7,193 | 382 | 1,017 | 1,479 | 1,432 | Upgrade
|
| Net Income | -3,711 | -7,193 | 382 | 1,017 | 1,479 | 1,432 | Upgrade
|
| Net Income to Common | -3,711 | -7,193 | 382 | 1,017 | 1,479 | 1,432 | Upgrade
|
| Net Income Growth | - | - | -62.44% | -31.24% | 3.28% | - | Upgrade
|
| Shares Outstanding (Basic) | 88 | 83 | 82 | 81 | 79 | 77 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 83 | 83 | 82 | 79 | 77 | Upgrade
|
| Shares Change (YoY) | 7.43% | -0.09% | 0.71% | 3.16% | 2.59% | 1.65% | Upgrade
|
| EPS (Basic) | -42.09 | -87.17 | 4.67 | 12.53 | 18.78 | 18.69 | Upgrade
|
| EPS (Diluted) | -42.09 | -87.18 | 4.63 | 12.40 | 18.59 | 18.50 | Upgrade
|
| EPS Growth | - | - | -62.66% | -33.30% | 0.49% | - | Upgrade
|
| Free Cash Flow | 1,742 | -6,077 | 9,675 | 6,902 | 4,580 | 3,170 | Upgrade
|
| Free Cash Flow Per Share | 19.76 | -73.65 | 117.14 | 84.16 | 57.61 | 40.91 | Upgrade
|
| Gross Margin | 81.46% | 75.70% | 94.05% | 94.73% | 91.39% | 91.25% | Upgrade
|
| Operating Margin | -4.46% | -81.46% | 18.06% | 39.01% | 9.66% | 9.87% | Upgrade
|
| Profit Margin | -12.68% | -56.34% | 2.45% | 5.74% | 16.73% | 14.72% | Upgrade
|
| Free Cash Flow Margin | 5.95% | -47.60% | 62.14% | 38.97% | 51.80% | 32.59% | Upgrade
|
| EBITDA | 2,658 | -7,921 | 4,157 | 8,188 | 2,204 | 2,449 | Upgrade
|
| EBITDA Margin | 9.08% | -62.05% | 26.70% | 46.23% | 24.93% | 25.18% | Upgrade
|
| D&A For EBITDA | 3,963 | 2,478 | 1,345 | 1,278 | 1,350 | 1,489 | Upgrade
|
| EBIT | -1,305 | -10,399 | 2,812 | 6,910 | 854 | 960 | Upgrade
|
| EBIT Margin | -4.46% | -81.46% | 18.06% | 39.01% | 9.66% | 9.87% | Upgrade
|
| Effective Tax Rate | - | - | 64.56% | - | 8.82% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.